The second patient is a 37-year-old HIV-positive male with XDR-TB. He was initiated on an individualized regimen of pyrazinamide (Z)-bedaquiline-delamanid-linezolid-clofazimine and para-amino salicylic acid (PAS) in January 2017. The baseline ECG was normal with QTcF-interval of 345 msec. He was admitted to hospital after five months of treatment with acute congestive heart failure (CHF). An ECG done on admission showed sinus rhythm with QTcF-interval of 488 msec. Bdq, Dlm, Z and PAS were all withheld because of the CHF, QTcF-interval prolongation, and mild elevation in liver enzymes on lab investigations. The patient responded well to CHF management and the QTcF-interval normalized within one week. The MDR-TB regimen was modified to ethambutol-linezolid-clofazimine-delamanid for the next three months after which bedaquiline was reintroduced. The patient took a Bdq and Dlm containing regimen for the next 11 consecutive months at which point he had completed 19 months of total duration of treatment and was discharged from treatment with an outcome of cure. As a result, the patient's QT-interval prolongation was likely to have resulted from the CHF, PAS or other factors.